Data Resource Profile: The Cancer Public Library Database in South Korea

• Published in: Cancer research and treatment 2024, 56(4), , pp.1014-1026
• Main Authors: Choi, Dong-Woo, Guk, Min Yeong, Kim, Hye Ri, Ryu, Kwang Sun, Kong, Hyun-Joo, Cha, Hyo Soung, Kim, Hyun-Jin, Chae, Heejung, Jeon, Young Sang, Kim, Hwanhee, Jung, Jipmin, Im, Jeong-Soo, Choi, Kui Son
• Format: Article
• Language: English
• Subjects: Databases, Factual; Female; Humans; Incidence; Male; Neoplasms - epidemiology; Registries; Republic of Korea - epidemiology; Special; 의학일반
• ISSN: 1598-2998; 2005-9256; 2005-9256
• DOI: 10.4143/crt.2024.207

This paper provides a comprehensive overview of the Cancer Public Library Database (CPLD), established under the Korean Clinical Data Utilization for Research Excellence project (K-CURE). The CPLD links data from four major population-based public sources: the Korea National Cancer Incidence Database in the Korea Central Cancer Registry, cause-of-death data in Statistics Korea, the National Health Information Database in the National Health Insurance Service, and the National Health Insurance Research Database in the Health Insurance Review & Assessment Service. These databases are linked using an encrypted resident registration number. The CPLD, established in 2022 and updated annually, comprises 1,983,499 men and women newly diagnosed with cancer between 2012 and 2019. It contains data on cancer registration and death, demographics, medical claims, general health checkups, and national cancer screening. The most common cancers among men in the CPLD were stomach (16.1%), lung (14.0%), colorectal (13.3%), prostate (9.6%), and liver (9.3%) cancers. The most common cancers among women were thyroid (20.4%), breast (16.6%), colorectal (9.0%), stomach (7.8%), and lung (6.2%) cancers. Among them, 571,285 died between 2012 and 2020 owing to cancer (89.2%) or other causes (10.8%). Upon approval, the CPLD is accessible to researchers through the K-CURE portal. The CPLD is a unique resource for diverse cancer research to investigate medical use before a cancer diagnosis, during initial diagnosis and treatment, and long-term follow-up. This offers expanded insight into healthcare delivery across the cancer continuum, from screening to end-of-life care.